FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:672-673 September 7, 1995 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by James S. Malpas, Daniel E. Bergsagel, and Robert A. Kyle. 581 pp. New York, Oxford University Press, 1995. $98. ISBN 0-19-262480-6.

The study of multiple myeloma has fascinated and challenged a multitude of workers in basic science and clinical medicine. Nevertheless, progress in treating this disease has been slow. The cause is unknown, and because the ancestral myeloma cell is unknown, biologic and molecular aspects of the disease are difficult to study. A major consequence of our ignorance is that therapeutic advances have been minimal.

Indeed, when I entered medical school in 1967, the sixth and last single-authored edition of Maxwell M. Wintrobe's Clinical Hematology (Philadelphia: Lea and Febiger) stated that the cause of multiple myeloma was unknown. As for treatment, . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.